Fiche publication
Date publication
juin 2025
Journal
JAMA oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe
,
Pr BOUCHE Olivier
Tous les auteurs :
Taïeb J, Sullo FG, Lecanu A, Bourreau C, Barbier E, Gandini A, Bez J, Mulot C, Di Fiore F, Elhajbi F, Borg C, Bouché O, Aparicio T, Zaanan A, André T, Tougeron D, Taly V, Laurent-Puig P
Lien Pubmed
Résumé
Immune checkpoint inhibitors (ICIs) have dramatically transformed the therapeutic landscape of deficient mismatch repair/microsatellite unstable-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC); however, ICI use is challenged by primary resistance and timing of discontinuation. Whether circulating tumor DNA (ctDNA) may be predictive of progression-free survival (PFS) and overall survival (OS) in this treatment context remains unknown.
Référence
JAMA Oncol. 2025 06 18;:
